Natural killer cells for immunotherapy

Clinical-grade natural killer (NK) cell isolation can be enabled in a two-step, fully automated manner within a closed system on the CliniMACS Prodigy. Additionally, it is possible to use the CliniMACS Prodigy for NK cell expansion or generation of engineered NK cells. 

Natural killer (NK) cell and CAR NK cell-based immunotherapies show an enormous potential for the treatment of several diseases. The interest of the field keeps growing and so do the possibilities. However, the isolation of NK cells can be challenging, and achieving a high purity of the NK cell population is an all-important first step.  Following this, isolated NK cells can either be applied directly, expanded for further use, or serve as starting material for NK cell engineering. 

The LP-3-56 Process allows fully automated in vitro depletion of CD3 expressing cells with optional subsequent in vitro enrichment of human CD56 expressing cells on the CliniMACS Prodigy. 

Workflow overview of the NK cell isolation process (LP-3-56) on the CliniMACS Prodigy. 

Cell separation on the CliniMACS Prodigy is a simple and easy method to magnetically isolate NK cells. This approach results in a pure NK cell population.

Depletion of T cells

In the first step, CliniMACS® CD3 MicroBeads are used to deplete T cells.

Optional enrichment of NK cells

In the second step, NK cells are enriched by positive isolation with CliniMACS CD56 MicroBeads. This results in an efficient depletion of both T and B cells, without inducing activation of NK cells.

NK cell expansion using NK MACS Medium (research use) and NK MACS GMP Medium
NK cell expansion using NK MACS Medium (research use) and NK MACS GMP Medium (Phenol Red)

NK MACS GMP Medium (Phenol Red) has been optimized for the cultivation, activation, and expansion of isolated human NK cells or NK cells from peripheral blood mononuclear cells (PBMCs). It is manufactured without animal-derived components. NK MACS GMP Medium (Phenol Red) is filled in flexible bags, making handling in GMP confirming processes easy.

Express Modes of the MACSQuant Instruments allow for fully automated and standardized flow cytometry processes.

In-process and quality controls (IPC/QC) are required for consistent cell manufacturing. Integrated sampling pouches on the CliniMACS® Tubing Sets allows for samples to be collected at any time during and at the end of the cell manufacturing process. Miltenyi Biotec provides complete solutions with our MACS Flow Cytometers, a wide portfolio of MACS IVD Antibodies, a time-saving and standardized staining procedure with StainExpress™ antibody cocktails, and automated flow cytometry analysis with Express Modes for clinical flow cytometry. 

When using a MACSQuant® Instrument, Express Modes allow for fully automated and standardized flow cytometry processes. The MACSQuant Instrument and the MACS Flow Cytometry Portfolio are for research use only. MACS IVD Antibodies are produced according to the quality management system ISO 13485.

  • Panch, S. et al. (2019) Robust Selections of various hematopoietic cell fractions on the CliniMACS Plus Instrument. Clin. Hematol. Int. 1(3): 161-167. 
  • Myers, J. A. and Miller, J. S.  (2020) Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 
  • Chiossone, L. et al. (2018) Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18: 671–688.
  • Hammer, Q. et al. (2018) Natural killer cell specificity for viral infections. Nat. Immunol. 19: 800-808.
  • Miller, J. S. et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051–3057.
  • Curti, A. et al. (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118: 3273–3279.
  • Bachanova, V. et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Immunother. 67: 483-94.
  • Talleur, A. C. et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. Biol. Blood Marrow Transplant. 23: 1910–1917.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.

Seems like you are coming from USA!
Do you want to visit our website in your country?